CD24 is a marker for human breast carcinoma - PubMed (original) (raw)
CD24 is a marker for human breast carcinoma
M Fogel et al. Cancer Lett. 1999.
Abstract
CD24 is a small, mucin-type glycosylphosphatidylinositol-linked cell surface molecule expressed by neutrophils, pre B lymphocytes and certain human tumor cell lines. CD24 has been identified as a ligand for P-selectin in both mouse and human cells. We previously reported that the P-selectin-CD24 binding pathway is important for the binding of the breast carcinoma cell line KS to platelets and the rolling of these cells on endothelial P-selectin. In the present study we have analyzed the expression of CD24 on human breast carcinoma cell lines and on fresh breast carcinoma specimens using the CD24-specific antibody ML-5. Our study clearly demonstrates that CD24 is abundantly expressed on cell lines and fresh tissues of breast carcinomas. We find a differential expression of CD24 in breast carcinomas (cytoplasmic pattern) versus benign breast lesions (apical pattern). Moreover, the intensity of CD24 expression increases with the histological grade of the tumor. Thus, CD24 expression might be a useful marker for human breast carcinoma and play a role in facilitating metastasis by the interaction between tumor cells and platelets or endothelial cells.
Similar articles
- High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: a preventive mechanism of malignant tumor cells against complement attack?
Hofman P, Hsi BL, Manie S, Fenichel P, Thyss A, Rossi B. Hofman P, et al. Breast Cancer Res Treat. 1994;32(2):213-9. doi: 10.1007/BF00665772. Breast Cancer Res Treat. 1994. PMID: 7532466 - CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells.
Aigner S, Sthoeger ZM, Fogel M, Weber E, Zarn J, Ruppert M, Zeller Y, Vestweber D, Stahel R, Sammar M, Altevogt P. Aigner S, et al. Blood. 1997 May 1;89(9):3385-95. Blood. 1997. PMID: 9129046 - Benign tumors of the breast with multinucleated stromal giant cells. Immunohistochemical analysis of six cases and review of the literature.
Ryska A, Reynolds C, Keeney GL. Ryska A, et al. Virchows Arch. 2001 Dec;439(6):768-75. doi: 10.1007/s004280100470. Virchows Arch. 2001. PMID: 11787849 Review. - CD24 and human carcinoma: tumor biological aspects.
Lim SC. Lim SC. Biomed Pharmacother. 2005 Oct;59 Suppl 2:S351-4. doi: 10.1016/s0753-3322(05)80076-9. Biomed Pharmacother. 2005. PMID: 16507407 Review.
Cited by
- Emerging Immune Checkpoint Molecules on Cancer Cells: CD24 and CD200.
Moon SY, Han M, Ryu G, Shin SA, Lee JH, Lee CS. Moon SY, et al. Int J Mol Sci. 2023 Oct 11;24(20):15072. doi: 10.3390/ijms242015072. Int J Mol Sci. 2023. PMID: 37894750 Free PMC article. Review. - IMM47, a humanized monoclonal antibody that targets CD24, exhibits exceptional anti-tumor efficacy by blocking the CD24/Siglec-10 interaction and can be used as monotherapy or in combination with anti-PD1 antibodies for cancer immunotherapy.
Li S, Chen D, Guo H, Yang Y, Liu D, Yang C, Bai X, Zhang W, Zhang L, Zhao G, Tu X, Peng L, Liu S, Song Y, Jiang Z, Zhang R, Yu J, Tian W. Li S, et al. Antib Ther. 2023 Sep 9;6(4):240-252. doi: 10.1093/abt/tbad020. eCollection 2023 Oct. Antib Ther. 2023. PMID: 37846296 Free PMC article. - Identification of CD24 as a marker of Patched1 deleted medulloblastoma-initiating neural progenitor cells.
Robson JP, Remke M, Kool M, Julian E, Korshunov A, Pfister SM, Osborne GW, Taylor MD, Wainwright B, Reynolds BA. Robson JP, et al. PLoS One. 2019 Jan 18;14(1):e0210665. doi: 10.1371/journal.pone.0210665. eCollection 2019. PLoS One. 2019. PMID: 30657775 Free PMC article. - CD24 expression and stem-associated features define tumor cell heterogeneity and tumorigenic capacities in a model of carcinogenesis.
Ortiz-Montero P, Liu-Bordes WY, Londoño-Vallejo A, Vernot JP. Ortiz-Montero P, et al. Cancer Manag Res. 2018 Nov 16;10:5767-5784. doi: 10.2147/CMAR.S176654. eCollection 2018. Cancer Manag Res. 2018. PMID: 30510447 Free PMC article. - CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator.
Moon YW, An HJ, Koo JS, Kim GM, Han H, Park S, Kim SI, Park HS, Kim S, Kim SK, Lee SA, Hwang S, Son GW, Sohn J. Moon YW, et al. Oncotarget. 2017 Dec 21;9(2):2622-2630. doi: 10.18632/oncotarget.23519. eCollection 2018 Jan 5. Oncotarget. 2017. PMID: 29416796 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical